Designed for Precision.
Developed for Life.
At Adcendo, we are developing a new generation of antibody-drug conjugates (ADCs) using a target and indication-driven approach to address cancers with high unmet medical need.
Our programs are designed from the outset to achieve the best possible balance of efficacy and tolerability, with the potential to deliver meaningful benefit for patients worldwide.
Latest News
Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Adcendo ApS to Present ADCE-D01 Phase 1 Clinical Data in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Press release